To develop neuroprotective drugs for multiple sclerosis and other neurological and ophthalmological diseases.
To identify new biomarkers for multiple sclerosis and to transform them into diagnostic and prognostic tests for the disease.
To pursue the development of combination therapies and personalized medicine.
To become a global biomedical company and a world leader in brain diseases, primarily focused on Multiple Sclerosis.
Innovation: We follow the paradigm of open innovation by incorporating promising therapeutic strategies for MS and other brain diseases from academic institutions, and guiding them through the preclinical and clinical stages.
Social Responsability: Our responsibility is towards society, towards our shareholders, towards our collaborators and towards the patients. Ethics and "savoir faire" is the hallmark of our business culture.
Ethics and Honesty: This is the mainstay of our company culture, both towards society and the healthcare services.
Implication: Only by implicating the most accomplished professionals can we achieve the best results in the shortest time. Our goal is clear and we will exhaust all possible means to achieve it.
Commitment: To health and the healthcare system, from a professional, scientific and human point of view.